A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive Patients
To evaluate the feasibility of Retrovir (AZT) in the treatment of psoriasis in HIV antibody positive patients. Retrovir has been shown to be effective in the treatment of AIDS. In addition, the administration of AZT appears to have induced a remission of psoriasis in one case study. In light of AZT's antiviral activity and potential effectiveness as an agent for the treatment of psoriasis, this would be the most likely treatment for HIV positive, psoriatic patients whose disease progresses quickly.
|Study Design:||Primary Purpose: Treatment|
|Official Title:||Retrovir Capsules in the Treatment of Psoriasis in HIV Antibody Positive Patients: A Pilot Study|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002286
|United States, North Carolina|
|Glaxo Wellcome Inc|
|Research Triangle Park, North Carolina, United States, 27709|